CalciMedica (CALC) Misses Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC)
August 14, 2024 6:48 AM EDTOppenheimer analyst Leland Gershall reiterated an Outperform rating and $20.00 price target on CalciMedica (NASDAQ: CALC)
The analyst comments "CALC reported on its development progress with CRAC channel inhibitor Auxora. Following the positive Phase 2b CARPO reveal in acute pancreatitis (AP) reported... More
